The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
Sage Therapeutics should be able to price its experimental depression pill at the "value it'll provide" for patients despite industry-wide political scrutiny over the cost of drugs, CEO Jeff Jonas told CNBC on Wednesday.
High prescription drug costs have become a rare bipartisan issue, as health care remains a top concern for voters in the upcoming November 2020 presidential election. The biopharmaceutical firm said Wednesday it is advancing its experimental oral drug, known as SAGE-217, for treatment-resistant depression. The drug could be lucrative for Sage, as roughly 20% of people with depression don't respond to available treatments.
When asked on CNBC's "Power Lunch " how the company expects to price the drug amid intense drug price rhetoric from Washington, Jonas said, "Every company pays attention to macro factors."
"We believe if [the drug] continues to perform the way it has, with rapid onset and durable effects, and not requiring chronic pharmacotherapy, that it really could be a game-changer," Jonas said. "It's premature to talk about pricing in that respect. But we feel we should be able to price it for the value it'll provide for patients."
In May, Novartis gave similar reasoning on the pricing for its drug treating spinal muscular atrophy. But it's quite different: a gene therapy for a muscle-wasting disease and leading genetic cause of infant mortality. That therapy, Zolgensma, is a one-time treatment. And, at $2.1 million, it's the most expensive drug in the world.
Earlier this year, Sage got approval from the Food and Drug Administration for Zulresso, the first postpartum depression drug. The drug, an injection, is designed to reduce symptoms of depression by targeting receptors of a neurotransmitter called GABA.
Sage's stock is up more than 82% year to date.